Long COVID Biomarkers: Blood Proteins May Finally Help Diagnosis

For millions of people suffering from the lingering effects of a SARS-CoV-2 infection, the journey has been frustrating and full of uncertainty. Patients often face skepticism because standard medical tests come back normal. However, a breakthrough study published in the journal Science has identified specific patterns in blood proteins that could finally offer a definitive diagnosis. This discovery suggests that Long COVID has a biological fingerprint, potentially leading to objective tests and targeted treatments.

The Breakthrough: Identifying the "Complement System"

Researchers at the University of Zurich and University Hospital Zurich have pinpointed a specific mechanism in the blood that separates Long COVID patients from those who recovered fully. The study, led by immunologist Dr. Onur Boyman, analyzed blood serum from 113 patients followed for up to a year after their initial infection.

The team discovered that patients with active Long COVID showed distinct changes in blood serum proteins related to the “complement system.” The complement system is a part of your innate immune system. Under normal circumstances, it helps your body fight off infection by activating inflammation and destroying pathogens. Once the virus is gone, this system should switch off.

In Long COVID patients, this switch appears to be broken. The research shows that the complement system remains hyperactive long after the acute infection has passed. This ongoing activity causes the immune system to attack healthy cells, leading to tissue damage and the wide variety of symptoms patients experience.

Key Findings from the Zurich Study

  • Active Biomarkers: Patients showed elevated levels of proteins involved in the complement system, specifically those related to the formation of the “membrane attack complex” (MAC).
  • Tissue Damage: The hyperactivity of these proteins leads to damage in blood vessel linings and red blood cells.
  • Correlation with Symptoms: The levels of these specific proteins correlated with the severity of symptoms like fatigue and brain fog.
  • Distinction: The protein signature was distinct enough to differentiate Long COVID patients from those who had recovered or those with other illnesses.

Why This Changes the Medical Landscape

Until now, Long COVID has been a diagnosis of exclusion. Doctors run tests for heart disease, lung issues, and autoimmune disorders. If everything comes back negative, the patient is diagnosed with Long COVID based on their reported symptoms. This lack of objective evidence has made it difficult for patients to access disability benefits, insurance coverage, or even basic medical validation.

The identification of these protein biomarkers provides the first step toward a standardized blood test. If a commercial lab test can be developed to detect these specific complement system proteins, doctors could diagnose the condition with the same certainty they use for diabetes or high cholesterol.

This shift from subjective symptoms to objective data is critical for the estimated 65 million people worldwide living with the condition. It moves the conversation from “psychological” causes to verifiable physiological dysfunction.

The Role of Microclots and Inflammation

While the Zurich study focuses on the complement system, it aligns with other research regarding blood abnormalities. The complement system interacts closely with the body’s coagulation (clotting) system. When the complement system is inflamed, it can trigger the blood to clot more easily.

Research from other institutions, such as the studies conducted by Resia Pretorius at Stellenbosch University, has highlighted the presence of “microclots” in the blood of Long COVID patients. These tiny clots trap inflammatory molecules and block oxygen from reaching tissues.

The connection between the complement system and clotting explains why patients experience such a broad range of symptoms:

  1. Fatigue: Poor oxygen delivery due to vascular damage or microclots.
  2. Brain Fog: Neuroinflammation caused by the immune system attacking healthy nerve cells or blood vessels in the brain.
  3. Exercise Intolerance: The inability of blood vessels to function correctly under stress due to ongoing endothelial damage.

Moving Toward Targeted Treatments

Perhaps the most exciting aspect of identifying these biomarkers is the potential for treatment. If the root cause is a dysregulated complement system, doctors can look at existing drugs that target this specific pathway.

Currently, there are medications used to treat rare blood disorders that work by inhibiting the complement system. Dr. Boyman and other researchers suggest that these existing therapies could be repurposed for Long COVID trials. This would significantly shorten the timeline for finding an effective treatment compared to developing a new drug from scratch.

Furthermore, companies like IncellDx are investigating other immune markers (cytokines) and have proposed treatments involving CCR5 antagonists to calm vascular inflammation. The validation of the complement system pathway adds another concrete target for pharmaceutical companies to pursue.

Challenges in Commercializing the Test

While the science is promising, patients cannot walk into a Quest Diagnostics or LabCorp tomorrow and ask for this test. Several hurdles remain before this becomes a standard of care:

  • Validation: The findings need to be replicated in larger, more diverse groups of patients to ensure the markers are consistent across different demographics and variants of the virus.
  • Standardization: Labs need to develop a standardized assay that is cost-effective and accurate. Current methods for analyzing these proteins are complex and typically used only in research settings.
  • Specificity: Researchers must ensure these protein markers are unique to Long COVID and do not overlap significantly with other autoimmune conditions like Lupus or Rheumatoid Arthritis.

Despite these hurdles, the discovery of a biological mechanism is a massive leap forward. It provides a roadmap for diagnostic companies and gives patients hope that a simple blood draw could soon validate their experience.

Frequently Asked Questions

Is there a blood test available now for Long COVID? No, there is currently no FDA-approved commercial blood test specifically for Long COVID. The protein biomarkers identified in the Zurich study are still in the research phase. However, this discovery lays the groundwork for such a test to be developed in the near future.

What is the complement system mentioned in the study? The complement system is a network of proteins in your blood that forms part of your immune defense. It helps clear out pathogens and damaged cells. In Long COVID patients, this system stays overactive, attacking healthy tissue and causing inflammation.

Can existing drugs treat this protein imbalance? Potentially. There are existing medications known as “complement inhibitors” used for other diseases. Researchers are now looking into whether these drugs could be safe and effective for treating Long COVID patients who show these specific biomarkers.

Does this study prove Long COVID is not psychological? Yes. The study provides concrete biological evidence of immune system dysfunction and tissue damage. It confirms that the symptoms patients experience are caused by physiological changes in the blood and immune system, not psychological factors.

Who conducted this research? The study was led by Dr. Onur Boyman, the director of the Department of Immunology at the University Hospital Zurich, and was published in the journal Science in January 2024.